AUTHORS
Yuki Nishida, MD, PhD, Edward Ayoub, PhD2, Hideaki Mizuno, MD, PhD3, Lauren Ostermann4, Darah A Scruggs, MS5, Po Yee Mak6, Bing Z Carter, PhD7, Abhishek Maiti, MBBS8, Yoonkyu Lee, PhD9, David Lehotzky, PhD10, Gaddy Getz, PhD11, Michael Andreeff, MD, PhD12
AFFILIATIONS
1 Section of Molecular Hematology and Therapy, Houston, Texas, United States
2 Section of Molecular Hematology and Therapy, Houston, Texas, United States
3 Section of Molecular Hematology and Therapy, Houston, Texas, United States
4 Section of Molecular Hematology and Therapy, Houston, Texas, United States
5 Section of Molecular Hematology and Therapy, Houston, Texas, United States
6 Section of Molecular Hematology and Therapy, Houston, Texas, United States
7 Section of Molecular Hematology and Therapy, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 Section of Molecular Hematology and Therapy, Houston, Texas, United States
10 Broad Institute of MIT and Harvard, Boston, Massachusetts, United States
11 Broad Institute of MIT and Harvard, Boston, Massachusetts, United States
12 Section of Molecular Hematology and Therapy, Houston, Texas, United States
ABSTRACT
Background:
TP53 mutations account for approximately 10% of de novo and 30% of relapsed/refractory acute myeloid leukemia (AML), with the most devastating outcome. Recent studies have shown the enrichment of immature and erythroid populations in TP53 mutated (TP53mut) AML, especially after venetoclax (Ven)-based therapies (Rodriguez-Meira, 2023; Daver, 2025; Waclawiczek, 2026). We reported MYC overexpression in ven-resistant (Ven-R) AML (Nishida et al. Sci Adv 2023), and targeted protein degradation of MYC and GSPT1 by GT19630 is highly effective in MYC-driven hematologic malignancies including ven-R AML (Nishida et al. Blood 2026, in press); however, cell populations where MYC is highly active, especially post Ven-containing therapies, and treatment strategies to target erythroid populations in TP53mut AMLs have not been developed.
Methods:
Paired single-cell RNA sequencing data (N = 55, including 3 normal bone marrow, 7 TP53wt and 19 TP53mut AML samples) were analyzed. Copy number variations (CNV) were inferred using numbat and copykat algorithms. A univariate linear model was applied to compute transcription factor (TF) activity for MYC per single cell based on collecTRI regulon network (Müller-Dott, 2023). Single-cell DNA sequencing + Protein (scDNAseq+Protein) was performed in 5 paired samples to detect TP53 mutations in differentiated cells. Single-cell mass cytometry (CyTOF) was used for primary TP53mut AML samples with surface and intracellular antibodies. Two patient-derived xenograft (PDX) models established from primary TP53mut AML samples were used for efficacy.
Results:
TP53mut AMLs had higher frequencies of CNV+ cells (45.6% vs 58.5% in TP53wt vs TP53mut, respectively). Strikingly, pseudotime analysis revealed CNV+ terminally differentiated erythroid cells and monocytes in TP53mut AMLs, while CNV+ cells were restricted to immature components in TP53wt AMLs. TP53 mutations were found in CD34+CD71+ cells and monocytes in TP53mut AML samples subjected to scDNAseq + Protein. MYC transcripts were significantly increased in TP53mut CNV+ hematopoietic stem cells/multipotent progenitors (HSC/MPP) compared to TP53wt CNV+ and NBM HSC/MPP. Consistently, the TF activity of MYC is significantly increased in TP53mut compared to TP53wt AML samples. MYC ranked as one of the top TFs among over 600 TFs in TP53mut AMLs, with increased ranking from #13 pre- to #3 post-treatment, suggesting increased activity of MYC post-treatment in TP53mut AMLs. Erythroid populations were enriched in TP53mut AML samples after Ven/Aza (Waclawizcek et al. 2026). MYC TF activity was significantly elevated post Ven/HMA in CNV+ HSC/MPP, megakaryoerythroid-mast cell progenitors (MEP), mid- and late erythroid cells in our and Waclawizcek scRNAseq cohorts (N = 4 in each cohort), suggesting that MYC is even more activated post ven/HMA, providing strong rationale to target MYC in TP53mut AMLs. GT19630 (GT), a dual MYC/GSPT1 proteolysis targeting chimera (Nishida et al. Blood, in press), induced synergistic cell death in combination with Ven/Aza in primary TP53mut AML samples (N = 7, mean Bliss index > 67). GT decreased CD34+CD38-, CD34+CD71+, CD34+CD38+, and CD34-CD14+ cells over 90%, but left CD34+CD38+CD71lowMYClow cells viable; Ven/Aza reduced CD34+CD38-BCL2high but did not reduce CD34+CD71+BCL2low and CD34-CD14+ cells. In contrast, GT+Ven/Aza effectively reduced all cell populations by > 99% determined by CyTOF. Lastly, GT + Ven/Aza significantly reduced CD71+CD235a+ erythroid cells and prolonged survival of mice carrying TP53mut AML cells compared to vehicle, GT or Ven/Aza in two different patient-derived xenograft (PDX) models.
Conclusion:
Our data suggest that MYC/GSPT1 degradation in combination with Ven/Aza is highly effective in residual erythroid as well as BCL2low immature cell populations in TP53mut AMLs. Toxicology and GMP-grade production are underway for GT in preparation of early-phase clinical trials.
DISCLOSURES
Yuki Nishida, MD, PhD: Sellas Biosciences - Research Funding; Kintor Pharmaceuticals - Research Funding